Clinical Trial Update: An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy [Phase 3]

View source ↗

Summary

Open-label extension study update for edasalonexent in boys with Duchenne muscular dystrophy; Phase 3 trial terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• edasalonexent (edasalonexent)

Snippet

Sponsor: Catabasis Pharmaceuticals | Conditions: Duchenne Muscular Dystrophy | Phase 3 | Status: TERMINATED